[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"International Agency for Research on Cancer\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":338},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,79,103,134,170,199,227,253,275,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100519361","novel-one-stop-affordable-point-of-care-and-ai-supported-system-of-screening-triage-and-treatment-selection-for-cervical-cancer-in-lmics-100519361",false,"NCT06042543","Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs","A Novel, One Stop, Affordable, Point of Care and Artificial Intelligence Supported System of Screening, Triage and Treatment Selection for Cervical Cancer and Precancer in the Low-to-middle Income Countries","EASTER","Inclusion Criteria:\n\n* No cervical screening during the previous 3 years\n* Between the ages of 25 and 49 years\n* Understands and signs a written informed consent form\n\nExclusion Criteria:\n\n* Refusal to take part for any reason\n* Actively menstruating or pregnant\n* Treated earlier for cervical precancer or cancer","FEMALE","25 Years","49 Years",{"count":21,"type":22},3200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Artificial intelligence (AI) is fast gaining reputation as a highly promising solution for cervical cancer screening. AI-based detection of cervical neoplasias is named automated visual exam (AVE) by the National Cancer Institute, USA. The investigators propose to develop and evaluate the performance characteristics of a novel AI system to both screen and triage women as well as help in treatment decision making. AI will analyse infrared spectroscopic signals derived from urine samples of unscreened women for the presence of high-risk human papillomavirus (hr-HPV). Our preliminary study has shown that spectroscopy can detect hr-HPV in urine. For screen-positive women the AI will interpret a set of cervical images captured with a high-quality devoted camera to detect high grade cervical precancers and cancers and to determine the type of transformation zone (TZ) (helps in treatment decision). The prototype device for image capture and the AI algorithms are already developed by us. The technologies will be further improved in part 1 (initial 2 years) and validated in part 2 (subsequent 3 years). During Part 1, the investigators will analyse urine samples collected from 1100 women at multiple screening clinics in Zimbabwe for the presence of hr-HPV using spectroscopy and use the signals generated to improve the AI algorithm. In this part the investigators will also assess the concordance between hr-HPV detection in urine samples using spectroscopy and cervical human papillomavirus (HPV) detection using a validated HPV test. The cervical image recognition device and the AI algorithm will be further improved during part 1 by collecting more images from hr-HPV positive and negative women. AI will also be trained to interpret the cervical images to determine the TZ type. In part 2 total 2100 women will be screened in Zimbabwe with AI-supported spectroscopic analysis of urine to detect hr-HPV and a validated HPV test to evaluate and compare their sensitivity and specificity to detect histology-proved high grade cervical precancers and cancers. The sensitivity and specificity of AI-supported detection of cervical neoplasias on cervical images will be evaluated to triage the HPV positive women. The accuracy of AI to determine TZ type will be compared with expert opinion. During the field validation part (part 2), the investigators will also conduct a cost analysis and compare cost of our approach to current standard Zimbabwean practice. The International Agency for Research on Cancer- World Health Organization WHO (IARC-WHO) has partnered with The Neo Sense Vector Company (NSV), Delaware, USA (industry), The Engineering Department, Lancaster University, Lancaster, UK and The University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe to implement this study focusing on innovation that will greatly contribute to the global elimination of cervical cancer, a WHO priority.",[28,29],"Cervical Cancer","Screening","RECRUITING","2026-05-27",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":34},"2023-12-09",{"date":38,"type":22},"2027-12-31",{"name":40,"class":41},"International Agency for Research on Cancer","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100640148","peripheral-vascular-disease-as-a-clinical-trigger-for-opportunistic-lung-cancer-screening-referral-an-implementation-study-100640148","NCT07598279","Peripheral Vascular Disease as a Clinical Trigger for Opportunistic Lung Cancer Screening Referral: An Implementation Study","Peripheral Vascular Disease as a Clinical Trigger for Opportunistic Lung Cancer Screening Referral: A Tertiary Care Implementation Study","PVD-Lungs","Inclusion Criteria:\n\n* All patients known\u002Fsuspected to have peripheral vascular disease attending specified clinics in the tertiary care hospital\n\nExclusion Criteria:\n\n* Prior diagnosis of lung cancer established\u002Fon work-up\n* Patients with no smoking history\n* Patients not eligible for low-dose CT scan","ALL","40 Years","80 Years",{"count":55,"type":22},355,[25],"The study aims to determine whether patients with peripheral vascular disease who attend the vascular clinics are eligible for lung cancer screening. This is because long-term cigarette smoking exposure is associated with peripheral vascular disease, and smoking is again the main risk factor for lung cancer.\n\nThese clinical encounters provide a potential opportunity to identify individuals who may qualify for lung cancer screening but are not routinely assessed for screening eligibility. Integrating systematic screening eligibility assessment within vascular clinics could therefore represent an effective strategy for identifying high-risk individuals and improving referral for lung cancer screening.\n\nAdditionally, peripheral arterial disease is commonly diagnosed using the ankle-brachial index (ABI), a non-invasive measure that compares systolic blood pressure between the ankle and brachial arteries. An ABI value below 0.90 is widely recognised as diagnostic of peripheral arterial disease and reflects the presence of systemic atherosclerosis.\n\nABI has been increasingly recognized as a marker of cumulative exposure to cardiovascular risk factors, particularly long-term tobacco smoking. Tobacco smoking contributes to endothelial dysfunction, chronic inflammation, and atherosclerotic plaque formation, mechanisms that are also implicated in lung carcinogenesis.\n\nBecause both lung cancer and peripheral vascular disease share major risk factors, ABI may serve as a clinical proxy indicator of cumulative smoking-related vascular damage. Individuals with lower ABI values may therefore represent a subgroup with higher cumulative tobacco exposure and potentially elevated lung cancer risk.\n\nEvaluating the association between ABI severity categories and lung cancer diagnosis may provide insights into whether vascular disease severity could help identify individuals who may benefit from targeted screening interventions. If an association is observed, ABI could potentially be used as a simple, routinely measured clinical indicator to prompt lung cancer screening assessment in vascular care settings.\n\nTherefore, this study will determine the proportion of the vascular disease patients who fall under the high-risk group for lung cancer screening and refer them to low-dose CT scan and follow-up them for the results and the adherence.",[59,60,61,62],"Lung Cancer","Peripheral Vascular Diseases","Ankle Brachial Index","Low Dose Computed Tomography",[64,65,66,67,68,69],"lung cancer","peripheral vascular disease","ankle brachial index","low dose computed tomography","lung cancer screening","opportunistic screening","NOT_YET_RECRUITING","2026-05-18",{"date":73,"type":34},"2026-05-20",{"date":33,"type":22},{"date":76,"type":22},"2027-03",{"name":40,"class":41},1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":78},"100407667","impact-of-hpv-vaccination-on-prevention-of-cervical-hpv-infection-in-sikkim-india-100407667","NCT04588402","Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India","Assessing the Population Level Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India","HPV-Vac-S","Inclusion Criteria:\n\n* Women aged 18 to 22 years, resident of Sikkim and married.\n* Pregnancy will not be considered as exclusion criteria.\n* Sample collection should be avoided during active menstruation.\n\nExclusion Criteria:\n\n* Women who do not provide written consent\n* Women who are not able to cooperate in collection of cervical cell sample or respond to questions due to any acute or severe mental and physical illnesses.\n* Women who had undergone hysterectomy.\n* Vaccinated in research project",true,"18 Years","22 Years",{"count":91,"type":22},5500,"OBSERVATIONAL","This project aims is to monitor the effectiveness of HPV vaccination in real-word conditions, at least 7 years after initiation of HPV vaccination in Sikkim. This study would give an opportunity to provide rapid feedback to the Indian public health authorities about the impact of the HPV vaccine.",[28],"2026-03-30",{"date":97,"type":34},"2026-04-03",{"date":99,"type":34},"2020-10-01",{"date":101,"type":22},"2026-12-31",{"name":40,"class":41},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":87,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":78},"100461238","using-artificial-intelligence-based-chatbot-to-improve-womens-participation-to-cervical-cancer-screening-programme-100461238","NCT05286034","Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme","Artificial Intelligence-assisted Decision-making to Improve Women's Participation to Cervical Cancer Screening in Occitanie Region-France","AppDate-You","Inclusion criteria: eligible women will be:\n\n* aged 30-65\n* did not perform a pap smear in the last 4 years\n* are living in deprived clusters in the Occitanie region.\n* did not answer to a first \"invitation\" letter to perform a clinician-collected HPV testing\n\nExclusion criteria: ineligible women will be those:\n\n* outside the target age group\n* had a Pap smear in the past 3 years\n* had hysterectomy including cervix\n* are pregnant\n* already scheduled a screening appointment or had just attended a HPV screening\n* had a cervical abnormality that was under exploration and\u002For treatment.\n* participated to the study pilot","30 Years","65 Years",{"count":114,"type":22},3000,[25],"This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive.",[118,28],"Cervical Cancer Screening",[120,121,122,123,124,125],"cervical neoplasia","cervical cancer screening","chatbot","artificial intelligence","cluster randomized controlled trial","HPV vaginal self-sampling","2026-03-25",{"date":128,"type":34},"2026-03-27",{"date":130,"type":34},"2025-11-03",{"date":132,"type":22},"2026-08-18",{"name":40,"class":41},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":87,"sex":51,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":156,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":78},"100612694","phase-4-a-trial-to-establish-non-inferiority-of-immunogenicity-of-a-single-dose-of-cervavac-quadrivalent-hpv-vaccine-compared-to-the-gardasil-quadrivalent-vaccine-among-girls-and-boys-aged-9-to-14-years-and-in-girlswomen-aged-15-to-20-years-in-zambia-100612694","NCT07256912","A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","CervALONE","Inclusion Criteria:\n\n1. Girl\u002Fwoman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.\n2. Participant willing to sign a written informed consent (for participants 18 years of age and above).\n3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).\n4. Participant or parent (s) willing to comply with all study requirements.\n5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.\n\nExclusion Criteria:\n\n1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.\n2. Participant has a known history of prior vaccination with any HPV vaccine.\n3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)\n4. Participant currently enrolled in any other clinical studies of investigational products.\n5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.\n6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.\n7. Participant has a history of any allergic diseases or severe allergic reaction to any agent\u002Fvaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).\n8. Participant has had an acute illness (moderate or severe) and\u002For fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.\n9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.\n10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.\n11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of \\>0.5 mg\u002Fkg\u002Fday), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.\n12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.\n13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.\n14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.\n15. Participant has history of any cancer, organ transplant or any other immune system disease.\n16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures","9 Years","20 Years",{"count":145,"type":22},1266,[147],"PHASE4","The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls\u002Fwomen aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls\u002Fwomen in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.",[150,151,152,153,154,155],"Vaccine Effectiveness","HPV Vaccination","Single Dose","Immunogenicity","Cervical Cancer Prevention","Quadrivalent HPV Vaccine",[157,158,159,160,161],"HPV","VACCINE","SINGLE DOSE","cervical cancer prevention","Quadrivalent HPV vaccine","2026-03-23",{"date":164,"type":34},"2026-03-24",{"date":166,"type":22},"2026-04-01",{"date":168,"type":22},"2029-01-15",{"name":40,"class":41},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":78},"100624247","triaging-of-women-detected-with-a-breast-lump-on-clinical-breast-examination-using-portable-ultrasound-device-100624247","NCT07407153","Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device","Ultrasound Based Triaging of Women With Breast Lump on Clinical Breast Examination: A Pilot Study, Indonesia, 2025-28","Ultra-3 CBE","Inclusion Criteria:\n\n* Women eligible for breast cancer screening as per the National screening programme in the country, and those detected with a breast lump on clinical breast examination\n\nExclusion Criteria:\n\n* Women already screened in the last three years\n* Women with known history of breast cancer or breast surgery\n* Symptomatic with high probability of breast cancer diagnosis (ulcerated lump, blood-stained nipple discharge etc.)\n* Debilitating illness\n* Unable to provide informed consent due to certain mental illnesses\n* Unlikely to be compliant to study procedures and\u002For follow up as determined by the investigator","69 Years",{"count":180,"type":22},600,[25],"This study aims to stratify women diagnosed with a lump in the breast by clinical breast examination(CBE) using a hand-held ultrasound machine. They will be stratified either with benign or potentially malignant lesion. As most of the lesions identified by CBE are benign, stratifying them (triage) avoids the unnecessary procedures in terms of mammography and biopsy. This will also reduce the burden in the further assessment sites, and provide better quality services in these places.",[184],"Breast Cancer",[186,187,188,189,190],"breast","breast carcinoma","triage","ultrasound","portable device","2026-02-06",{"date":193,"type":34},"2026-02-12",{"date":195,"type":34},"2025-06-01",{"date":197,"type":22},"2028-04-30",{"name":40,"class":41},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":51,"minAge":88,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100607782","peer-led-intervention-to-reduce-alcohol-binge-drinking-among-university-students-in-romania-100607782","NCT07193030","Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania","Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania- A Pilot Study Of The Implementation Processes","Inclusion Criteria:\n\n* University students currently enrolled in full-time undergraduate or postgraduate programs at Babeș-Bolyai University in Romania\n* Able to provide informed consent\n* Willing to participate in an in-person session\n* Alcohol status: AUDIT-C scoring 3 or above in females, 4 or above in males\n\nExclusion Criteria:\n\n* Students currently receiving treatment for alcohol dependence or any other substance use disorder\n* Students with a diagnosed severe mental health condition that may impair participation\n* Participation in any similar alcohol reduction program in the past 6 months.\n* Abstinent from alcohol consumption.",{"count":207,"type":22},120,[25],"The goal of this clinical trial is to learn if a behavioural intervention to change binge drinking habits in university students in Romania is feasible. The main research question is:\n\nIs a peer-led Alcohol Brief Intervention feasible to be implemented in a Romanian University to reduce binge drinking among students?\n\nResearchers will compare brief intervention (counselling) to no intervention.\n\nStudent participants will:\n\n1. Receive brief counselling for 15-20 minutes by their peers who were trained.\n2. Report their alcohol consumption levels in three surveys conducted over three months.",[211,212],"Binge Alcohol Consumption","Binge Drinking",[214,215,216,217,218],"Binge drinking","Alcohol Brief Intervention","Behaviour change wheel","University students","Romania","2025-09-25",{"date":221,"type":34},"2025-10-01",{"date":223,"type":22},"2026-03-01",{"date":225,"type":22},"2026-10-30",{"name":40,"class":41},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":87,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":42},"100573712","hpv-self-sampling-in-the-general-population-100573712","NCT06749847","HPV Self-sampling in the General Population","HPV Self-sampling in the General Population: Efficacy, Feasibility, Acceptability and Cost-effectiveness","MIRABELLE","Inclusion Criteria:\n\n* Women aged 30 to 65 years old\n* Living in the study area (Departments of Marne and Aube, France)\n* At moderate risk of cervical cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter)\n\nExclusion Criteria:\n\n* Outside the target age (less than 30 years old, or 66 years old and more)\n* Already participating in the current screening round\n* Total hysterectomy\n* History of cervical cancer\n* Current follow-up for abnormal cervical screening result or cervical lesions",{"count":236,"type":22},6000,[25],"A randomized controlled trial comparing three strategies for cervical cancer screening: direct mailing of HPV self-sampling kit (\"Outreach\" arm), choice between self-sampling or healthcare provider sampling (\"Choice\" arm), and standard care (control arm) in two French departments.",[28],[241,242,243,244,245],"Cervical cancer","screening program","pilot project","randomised control trial","France","2025-07-22",{"date":248,"type":34},"2025-07-23",{"date":250,"type":34},"2025-06-26",{"date":101,"type":22},{"name":40,"class":41},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":87,"sex":17,"minAge":143,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100296873","precama-molecular-subtypes-of-premenopausal-breast-cancer-in-latin-american-women-100296873","NCT03144648","PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women","Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study","PRECAMA","Inclusion Criteria:\n\n* woman between 20 and 45 years old\n* woman less than 3 years older or younger than the case\n* living in the area that the study is taking place during the past 3 years\n* woman menstruated at least once in the past 12 months\n* woman diagnosed with a primary breast cancer by histopathological examination (only for cases)\n\nExclusion Criteria:\n\n* woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)\n* woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)\n* woman suffering from chronic kidney failure\n* woman having a pathology that will hinder adequate communication\n* woman who is pregnant or nursing\n* woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)\n* any other reason to exclude","45 Years",{"count":114,"type":22},"Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival.\n\nTo improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study).\n\nPRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following:\n\n1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols\n2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes\n3. To improve the identification of specific endogenous\u002Fexogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes.\n4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer.\n\nThe results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.",[265],"Breast Cancer Female","2025-05-01",{"date":268,"type":34},"2025-05-06",{"date":270,"type":34},"2012-10-12",{"date":272,"type":22},"2025-12-30",{"name":40,"class":41},13,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":87,"sex":51,"minAge":52,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":78},"100212860","phase-4-multicentric-randomized-study-of-h-pylori-eradication-and-pepsinogen-testing-for-prevention-of-gastric-cancer-mortality-100212860","NCT02047994","Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality","GISTAR","Inclusion Criteria:\n\n* Men and women aged 40-64 at the time of signing the consent form\n* Willingness to get involved in the study irrespective in which of the study arms (after detailed information on the potential benefits and risks that this study may confer)\n* The person has signed a consent form (including the acceptance of transporting the samples over the borders, as appropriate)\n* To be in good health, as determined by a physical examination and history performed by a study physician at enrolment\n\nExclusion Criteria:\n\n* Personal history of gastric cancer (prevalent gastric cancer cases will not be revealed at the time of inclusion, and therefore will be included)\n* Gastric resections due to benign disease (ulcer suturing and vagotomy are accepted)\n* H. pylori eradication therapy within 12 months prior to inclusion (irrespective of the treatment result)\n* Presence of alarm symptoms for digestive or any other diseases (detailed in the questionnaire or during the physician evaluation)\n* Pathological findings at physical investigation suggestive for a serious organic disease (physician evaluation)\n* Serious co-morbid condition with life expectancy less than 5 years (physician evaluation)\n* Factors otherwise limiting the participation according to the protocol conditions (problems of mobility, etc.)\n* Serious psychological conditions\u002Fpsychiatric disease limiting the possibilities to understand the requirements for diagnostic and\u002For medical interventions (physician evaluation)\n* Low expectations on the compliance for the diagnostic work-up or treatment (physician evaluation)\n* Expected loss for the follow-up (e.g. lack of communication possibilities and data entry in the registries, expected travel abroad, etc.) (physician evaluation)\n* Signed consent form is not available","64 Years",{"count":284,"type":22},30000,[147],"Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation\u002Fmanagement group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I\u002FII ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.",[288,289,290],"Helicobacter Pylori Infections","Atrophic Gastritis","Gastric Cancer",[292,293,294,295,296,297],"Gastric cancer","Gastric cancer mortality","Helicobacter pylori treatment","Pepsinogen testing","Endoscopy","Volatile marker","2025-04-30",{"date":300,"type":34},"2025-05-02",{"date":302,"type":34},"2013-03",{"date":304,"type":22},"2035-12",{"name":40,"class":41},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100452578","phase-3-integration-of-hpv-vaccination-and-hpv-based-cervical-screening-into-arv-clinics-the-h2victory-trial-100452578","NCT05173324","Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial","Integration of HPV Vaccination and HPV-based Cervical Screening in Young Adult WLWH Into ARV Clinics to Speed the Pathway Towards Cervical Cancer Elimination: the H2VICTORY Trial","H2VICTORY","Inclusion Criteria:\n\n* Women living with HIV (WLWH)\n* Aged 25-35 years\n* Attending ARV clinics\n* Mentally competent to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Less than 3 months postpartum\n* Women without a cervix (e.g., hysterectomy)\n* Plans to move to another city in the next 2 years or any other reason to prevent finalizing the study","35 Years",{"count":316,"type":22},8000,[318],"PHASE3","A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce. Available HPV vaccines only prevent new infections. Since a large fraction of WLWH is already infected with HPV (\\>50%), vaccines' efficacy to prevent HPV infections (and therefore cervical disease) in this population is limited. Current WHO cervical cancer screening guidelines recommend treatment of the transformation zone (TZ) of WLWH who harbor HPV infections either at initial screening or one year later. Therefore, HPV vaccination at the time of the screening may improve vaccines efficacy conferring protection to newly growing cells of the treated TZ against HPV infections\u002Fre-infections. Consequently, a dual-intervention of HPV vaccination and HPV-based cervical screening in WLWH may alleviate the burden of HPV-related disease by improving HPV vaccination efficacy while extending cervical screening intervals. Nevertheless, implementing the dual-intervention may be challenging particularly in some contexts without well-established cervical cancer screening such as sub-Saharan African (SSA) countries. However, in these countries, at least 60% of PLWH regularly attend ARV clinics to be monitored and receive ARV treatment (cART). Therefore, integrating the dual-intervention into ARV clinics seems to be an efficient approach to reduce loss to follow-up while improving overall coverages of HPV vaccination and cervical screening. Such integration may also facilitate the implementation of a platform for the delivery of other HPV-related preventive measures such as HPV therapeutic vaccines.\n\nNevertheless, little is known about the efficacy of HPV vaccination in WLWH to prevent HPV infections and HPV-related diseases, especially in young adults. Moreover, evidence on how best to conduct cervical cancer prevention, particularly recently released WHO guidelines, through ARV clinics is limited. Therefore, IARC\u002FWHO in collaboration with HRP\u002FWHO and colleagues in SSA proposes to conduct a hybrid effectiveness-implementation trial (H2VICTORY) to evaluate the effectiveness of the dual-intervention of HPV vaccination and HPV-based cervical screening to reduce HPV infections (and therefore, the risk of cervical cancer) in WLWH aged 25-35 years while conducting implementation research to identify facilitators and barriers for adoption and sustainability of proven evidence-based cervical cancer prevention approaches integrated into ARV clinics across sub-Saharan Africa.",[321],"HPV Infection",[323,324,325,326,327,328,329],"HPV vaccination","HPV-based cervical screening","HIV infection","Cervical ablative treatment","Antiretroviral clinics","Implementation research","Hybrid effectiveness-implementation trials","2022-08-02",{"date":332,"type":34},"2022-08-03",{"date":334,"type":22},"2023-02-01",{"date":336,"type":22},"2027-06-30",{"name":40,"class":41},""]